Instability of vaccines often emerges as a key challenge during clinical development (lab to
clinic) as well as commercial distribution (factory to patient). To yield stable, efficacious …

Hepatitis B virus (HBV) infection has been a major global cause of morbidity and mortality.
The recognition of the problem led to a worldwide effort to reduce transmission of HBV …

Among 12billion injections administered annually, unsafe delivery leads to> 20million
infections and> 100million reactions. In an emerging new concept, freeze-dried plant cells …

Despite the various vaccines that have been developed to combat the coronavirus disease
2019 (COVID-19) pandemic, the persistent and unpredictable mutations of the severe acute …

New insights in vaccine development, the need for safe, economic and efficient vaccine
administration and the increasing mechanistic knowledge of immune responses induced by …

Hepatitis B Virus (HBV) is a significant public health challenge. Around 250 million people
live with chronic HBV infection. With a global approach to this issue, we focus on new …

The generation of strong pathogen-specific immune responses at mucosal surfaces where
hepatitis B virus (HBV) transmission can occur is still a major challenge. Therefore, new …

The use of tailored particle-based adjuvants constitutes a promising way to enhance antigen-
specific humoral and cellular immune responses. However, a thorough understanding of the …

Main conclusion Transgenic papaya callus lines expressing the components of the S3Pvac
vaccine constitute a stable platform to produce an oral vaccine against cysticercosis caused …

In the search for an optimal approach for the transcutaneous immunization (TCI) of hepatitis
B surface antigen (HBsAg), two vesicle formulations, L595 vesicles (composed of sucrose …